Floatz Rating
B58/100
Confidence
Indicative
Sponsor
St. Jude Children's Research Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05468359CT.gov Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | — | Recruiting | — | — | — |
NCT02638428CT.gov Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Childhood Malignant Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sorafenib (this asset) | St. Jude Children's Research Hospital | P2 | B · 58 |
| (+)-Vincristine | Tianjin Medical University Cancer Institute and Hospital | P2 | BB |
| Cyclophosphamide | St. Jude Children's Research Hospital | P2 | BB |
| Nivolumab | Australian & New Zealand Children's Haematology/Oncology Group | P2 | B |
| Irinotecan | Australian & New Zealand Children's Haematology/Oncology Group | P1/2 | B |
| Isocyclophosphamide | Samsung Medical Center | P2 | B |
| Epirubicin | Children's Hospital Medical Center, Cincinnati | P2 | B |
| OTL-38 | Mayo Clinic | P3 | B |
| Carboplatin | Samsung Medical Center | P2 | B |
+42 more in the Childhood Malignant Neoplasm cohort
Other indications for Sorafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P4 | BBB · 79 |
| Portal Vein Thrombosis | — | P4 | BBB · 74 |
| Adult Hepatocellular Carcinoma | — | P3 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- (+)-VincristineTianjin Medical University Cancer Institute and HospitalBB
- CyclophosphamideSt. Jude Children's Research HospitalBB
- NivolumabAustralian & New Zealand Children's Haematology/Oncology GroupB
- IrinotecanAustralian & New Zealand Children's Haematology/Oncology GroupB
- IsocyclophosphamideSamsung Medical CenterB
Citation
Floatz Terminal. Sorafenib in Childhood Malignant Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sorafenib-childhood-malignant-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →